Browse

Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer

DC Field Value Language
dc.contributor.authorKim, Jin Won-
dc.contributor.authorCho, Sung-Yup-
dc.contributor.authorChae, Jeesoo-
dc.contributor.authorKim, Ji-Won-
dc.contributor.authorKim, Tae-Yong-
dc.contributor.authorLee, Keun-Wook-
dc.contributor.authorOh, Do-Youn-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorIm, Seock-Ah-
dc.date.accessioned2021-01-31T12:00:30Z-
dc.date.available2021-01-31T12:00:30Z-
dc.date.issued2020-10-
dc.identifier.citationCancer Research and Treatment, Vol.52 No.4, pp.1178-1187-
dc.identifier.issn1598-2998-
dc.identifier.other114630-
dc.identifier.urihttps://hdl.handle.net/10371/173203-
dc.description.abstractPurpose Microsatellite instability (MSI) status may affect the efficacy of adjuvant chemotherapy in gastric cancer. In this study, the clinical characteristics of MSI-high (MSI-H) gastric cancer and the predictive value of MSI-H for adjuvant chemotherapy in large cohorts of gastric cancer patients were evaluated. Materials and Methods This study consisted of two cohorts. Cohort 1 included gastric cancer patients who received curative resection with pathologic stage IB-IIIC. Cohort 2 included patients with MSI-H gastric cancer who received curative resection with pathologic stage II/III. MSI was examined using two mononucleotide markers and three dinucleotide markers. Results Of 359 patients (cohort 1), 41 patients (11.4%) had MSI-H. MSI-H tumors were more frequently identified in older patients (p < 0.001), other histology than poorly cohesive, signet ring cell type (p=0.005), intestinal type (p=0.028), lower third tumor location (p=0.005), and absent perineural invasion (p=0.027). MSI-H status has a tendency of better disease-free survival (DFS) and overall survival (OS) in multivariable analyses (hazard ratio [HR], 0.4; p=0.059 and HR, 0.4; p=0.063, respectively). In the analysis of 162 MSI-H patients (cohort 2), adjuvant chemotherapy showed a significant benefit with respect to longer DFS and OS (p=0.047 and p=0.043, respectively). In multivariable analysis, adjuvant chemotherapy improved DFS (HR, 0.4; p=0.040). Conclusion MSI-H gastric cancer had distinct clinicopathologic findings. Even in MSI-H gastric cancer of retrospective cohort, adjuvant chemotherapy could show a survival benefit, which was in contrast to previous prospective studies and should be investigated in a further prospective trial.-
dc.subjectMicrosatellite instability-
dc.subjectAdjuvant chemotherapy-
dc.subjectStomach neoplasms-
dc.titleAdjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer-
dc.typeArticle-
dc.contributor.AlternativeAuthor임석아-
dc.identifier.doi10.4143/crt.2020.313-
dc.citation.journaltitleCancer Research and Treatment-
dc.identifier.scopusid2-s2.0-85093889819-
dc.citation.endpage1187-
dc.citation.number4-
dc.citation.startpage1178-
dc.citation.volume52-
dc.identifier.urlhttps://www.e-crt.org/journal/view.php?doi=10.4143/crt.2020.313-
dc.identifier.rimsid114630-
dc.identifier.sci000579859000018-
dc.identifier.kciidART002636271-
dc.description.isOpenAccessY-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
dc.contributor.affiliatedAuthorIm, Seock-Ah-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse